Humatrope ® (somatropin)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Humatrope Summary of Product Characteristics (SmPC)

Humatrope® (somatropin): Contraindications

Humatrope (somatropin) must not be used when there is any evidence of activity of a tumour. Somatropin should not be used in some patients

Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting GH therapy. Treatment should be discontinued if there is evidence of tumour growth.

Humatrope should not be reconstituted with the supplied solvent for patients with a known sensitivity to either metacresol or glycerol.

Humatrope should not be used for growth promotion in children with closed epiphyses.

Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Reference

Humatrope Summary of Product Characteristics

Date of Last Review: February 01, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question